三羟甲基甲胺基丙磺酸钠盐 | 91000-53-2

• 物质功能分类: 有机原料 - 氨基化合物 - 磺酸类氨基化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 三羟甲基甲胺基丙磺酸钠盐
• 中文别名: 3-[N-[三(羟甲基)甲基]氨基]丙磺酸钠；N-三(羟甲基)甲基-3-氨基丙磺酸钠盐；N-三(羟甲基)甲基-3-氨基丙烷磺酸钠盐；三羟甲基甲胺基丙磺酸 钠盐
• 英文名称: Sodium 3-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)propane-1-sulfonate
• 英文别名: sodium;3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propane-1-sulfonate
• CAS: 91000-53-2
• 化学式: C7H16NNaO6S
• 分子量: 265.26
• InChiKey: FEGYIWVHCSRXCG-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -5.77
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29225090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H315,H319,H335

文献信息

• OPHTHALMIC COMPOSITION COMPRISING ATROPINE OR ATROPINE SULPHATE
  申请人：Sydnexis, Inc.

  公开号：EP3689350A1

  公开（公告）日：2020-08-05

  Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

  本文提供了一种眼科组合物。在某些实施方案中，眼科组合物包括用于治疗眼科疾病或症状的低浓度眼科制剂；以及眼科可接受载体，其中眼科制剂在整个眼科可接受载体中分布均匀。本文进一步公开了一种眼科组合物，包括低浓度的眼科药剂和氘化水。本文还公开了通过向有需要的人的眼睛施用有效量的本文所述眼科组合物来阻止或预防近视发展的方法。
• Ophthalmic Composition
  申请人：Sydnexis, Inc.

  公开号：US10076515B2

  公开（公告）日：2018-09-18

  Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

  本文提供了一种眼科组合物。在某些实施方案中，眼科组合物包括用于治疗眼科疾病或症状的低浓度眼科制剂；以及眼科可接受载体，其中眼科制剂在整个眼科可接受载体中分布均匀。本文进一步公开了一种眼科组合物，包括低浓度的眼科药剂和氘化水。本文还公开了通过向有需要的人的眼睛施用有效量的本文所述眼科组合物来阻止或预防近视发展的方法。
• Ophthalmic composition
  申请人：Sydnexis, Inc.

  公开号：US10201534B2

  公开（公告）日：2019-02-12

  Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

  本文提供了一种眼科组合物。在某些实施方案中，眼科组合物包括用于治疗眼科疾病或症状的低浓度眼科制剂；以及眼科可接受载体，其中眼科制剂在整个眼科可接受载体中分布均匀。本文进一步公开了一种眼科组合物，包括低浓度的眼科药剂和氘化水。本文还公开了通过向有需要的人的眼睛施用有效量的本文所述眼科组合物来阻止或预防近视发展的方法。
• D2O stabilized pharmaceutical formulations
  申请人：SYDNEXIS, INC.

  公开号：US11052094B2

  公开（公告）日：2021-07-06

  Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

  本文提供了一种用氘化水配制的眼科组合物。本文还公开了通过向有需要的人的眼睛施用有效量的本文所述眼科组合物来治疗、改善或减轻眼科状况或疾病的方法。
• POLY AND COPOLY (N -VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS
  申请人：Applied Biosystems Inc.

  公开号：EP1636279B1

  公开（公告）日：2009-02-18